SCHEDULE: Opaleye Management Discloses 4.8% Stake in Larimar Therapeutics
Beneficial Ownership Report
Opaleye Management, L.P., and James Silverman have disclosed a 4.80% beneficial ownership stake in Larimar Therapeutics, Inc. common stock.
Summary
- Opaleye Management, Inc., Opaleye, L.P., and James Silverman collectively reported beneficial ownership of 4,110,000 shares of Larimar Therapeutics, Inc. Common Stock.
- This ownership represents 4.80% of the class of securities.
- The reporting persons share both voting and dispositive power over all 4,110,000 shares.
- The filing is a voluntary amendment to Schedule 13G, indicating a passive investment intent.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of Larimar Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G) indicating a passive investment. It contains no positive or negative operational or financial news, thus maintaining a neutral sentiment.
Future Outlook
NA
Management Comments
- Opaleye Management, Inc., Opaleye, L.P., and James Silverman certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Industry Context
This filing is a routine disclosure of a passive investment stake by an investment adviser and its related entities. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that an investment firm has taken a position in a biotechnology company.
Stakeholder Impact
- Shareholders: Disclosure of a significant passive stake by an institutional investor may be viewed positively as a vote of confidence, though the impact is generally limited given the passive nature.
Key Dates
| Date | Description |
|---|---|
| 08/29/2025 | Date of event which requires filing of this statement and execution of Joint Filing Agreement. |
Keywords
Larimar Therapeutics, Opaleye Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment, Passive Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.